 Prostate cancer ranks second in global mortality rates, with bone metastasis resulting from advanced cases affecting up to 90% of patients. These metastatic lesions can cause severe skeletal-related events, which traditional diagnostics such as tissue biopsies and imaging drawbacks. Biomarkers such as OPN, KCP, OPG, PENP, ALP, OC, CTX, NTX, TRAC, DPYD, PYD, ICTP, PSA, CGA, NSE, ProGRP, MRNA, CTDNA, and exosomes may be used to diagnose bone metastasis and predict patient outcomes. This article was authored by Ming Shuiying, Jianxue Mao, Ling Chaosheng, and others.